Peter J. Späth

TL;DR: This supplement contains work presented at the third workshop and expanded content toward a definitive picture of angioedema in the absence of allergy, and includes cumulative genetic investigations; multinational laboratory diagnosis recommendations; current pathogenesis hypotheses; and suggested prophylaxis and acute attack treatment.

TL;DR: Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches.

TL;DR: There is a paucity of double-blind, placebo-controlled trials on the treatment of HAE, making levels of evidence to support the algorithm less than optimal.

TL;DR: Immunomodulatory and anti‐inflammatory properties are based on multiple mechanisms of action which are effective concomitantly and synergistically at every occasion of use of IVIG in inflammatory and autoimmune disorders.

TL;DR: In patients with the complement-dependent autoimmune disease, dermatomyositis, IVIG had an immediate and long-lasting attenuating effect on complement amplification in vivo, despite the fact that it induced classical complement pathway activation.